Evidence map›Paper›PMID 24018392›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

Marcos de Lima, David L Porter, Minoo Battiwalla, Michael R Bishop, Sergio A Giralt, Nancy M Hardy, Nicolaus Kröger, Alan S Wayne, Christoph Schmid

2 registry-linked trialsOpen access · hybridAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03821519 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation

TypeinterventionalSponsorA.O. Ospedale Papa Giovanni XXIIIRan2019 to 2023Enrolled20ConditionsRelapsed Hematologic MalignancyArmsdonor-derived CIK cells
NCT06125483 narecruitingnot on this mapstarted 2023, after this paper: background citation

A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT

TypeinterventionalSponsorThe First Affiliated Hospital of Soochow UniversityRan2023 to 2026Enrolled38ConditionsHematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell TransplantationArmsUmbilical Cord Blood Transplantation
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Human CD34Cellular and molecular life sciences : CMLS · 2023
    Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 2 countries.

Marcos de LimaHematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
David L PorterBlood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Minoo BattiwallaHematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland.
Michael R BishopSection of Hematology/Oncology, University of Chicago Medicine, Chicago, Illinois.
Sergio A GiraltDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Nancy M HardyExperimental Transplantation Immunology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland. Electronic address: hardyn@mail.nih.gov.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alan S WaynePediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland; Current: Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.
Christoph SchmidKlinikum Augsburg, University of Munich, Munich, Germany.
Case Western Reserve University · USChildren's Center · USHospital of the University of Pennsylvania · USMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USNational Heart Lung and Blood Institute · USUniversity Hospital Augsburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Chicago · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

In the Second Annual National Cancer Institute's Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the first relapse workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed pre-emptive and maintenance strategies to prevent relapse after transplantation, for example, recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI, combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways.

Indexed as

Graft vs Tumor EffectHematopoietic Stem Cell TransplantationTransplantation ConditioningAntineoplastic AgentsCell- and Tissue-Based TherapyGraft vs Host DiseaseHematologic NeoplasmsHumansLymphocyte DepletionMyeloablative AgonistsNational Cancer Institute (U.S.)Secondary PreventionSurvival AnalysisT-LymphocytesTransplantation, HomologousUnited StatesAntineoplastic AgentsMyeloablative AgonistsAllogeneicPreventionRelapseStem cell transplantationTreatment

Identifiers

PMID24018392
PMCPMC3938421
OpenAlexW2003289575

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.